ABSTRACT
OBJECTIVE: To explore patient preference for injectable therapy over open surgery in the treatment of urinary incontinence. MATERIAL AND METHODS: Fifty-eight female patients presented for treatment of urinary incontinence. During the initial interview process, they were asked to quantify their preference for injectable therapy over surgery by specifying the lowest success rate they would accept and still try injectable therapy. The results were summarized and assessed in relation to patient age and history of previous urogynecologic surgery. RESULTS: The mean lowest acceptable success rate for all 58 surveyed patients was 34 percent, with 23 (40 percent) accepting a success rate of only 10 percent. Although not statistically significant, the data suggested that older patients may tend to accept lower success rates than younger patients (mean of 39 percent for patients aged less than 60 years compared to 22 percent for those aged 80 years or older). There was no difference in response based on history of previous urogynecologic surgery. CONCLUSION: Patients appear willing to accept a relatively low success rate for injectable therapy compared to open surgery.
Subject(s)
Humans , Female , Adult , Middle Aged , Aged, 80 and over , Biocompatible Materials/administration & dosage , Patient Satisfaction , Urinary Incontinence, Stress/therapy , Age Factors , Injections , Interviews as Topic , Urinary Incontinence, Stress/surgeryABSTRACT
We report the case of a postmenopausal woman with a synchronous obstructing intrinsic endometrioma of the left ureter and a coexistent periurethral leiomyoma. Endometriosis in postmenopausal women is a rare clinical entity usually associated with exogenous estrogen use. Urethral leiomyomas are also rare, with only 40 cases reported in the literature. Ovarian hormones are believed to influence the growth of leiomyomas. We report the genitourinary presentation of 2 separate disease entities with known hormonal influence in a postmenopausal woman receiving estrogen replacement therapy. We believe the patient's hormonal milieu affected the development of her concurrent pathology.